Category Research

Arrowhead Highlights Clinical-Stage RNAi Therapies for Obesity and Metabolic Diseases

Arrowhead Highlights Clinical-Stage RNAi Therapies for Obesity and Metabolic Diseases

Arrowhead Highlights Clinical-Stage RNAi Therapies for Obesity and Metabolic Diseases Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) recently showcased promising preclinical data supporting the advancement of two first-in-class, RNA interference (RNAi)-based investigational therapeutics, ARO-INHBE and ARO-ALK7, for the treatment of obesity and…

Read MoreArrowhead Highlights Clinical-Stage RNAi Therapies for Obesity and Metabolic Diseases

Parse Biosciences Progresses Towards Launching Single-Cell Chromatin Accessibility Products

Parse Biosciences Progresses Towards Launching Single-Cell Chromatin Accessibility Products Parse Biosciences, a leading innovator in scalable and accessible single-cell sequencing technology, has reaffirmed its commitment to advancing its Evercode™ single-cell chromatin accessibility products. This announcement marks a significant milestone for…

Read MoreParse Biosciences Progresses Towards Launching Single-Cell Chromatin Accessibility Products
Gensaic Partners with Novo Nordisk to Advance Next-Gen Precision Therapies

Gensaic Partners with Novo Nordisk to Advance Next-Gen Precision Therapies

Gensaic Partners with Novo Nordisk to Advance Next-Gen Precision Therapies Gensaic, Inc., a pioneering biotechnology company leveraging AI-driven protein design and biological insights to develop precision ligands for targeted drug delivery, has announced a major discovery and license collaboration with…

Read MoreGensaic Partners with Novo Nordisk to Advance Next-Gen Precision Therapies
SOTIO Presents Promising Preclinical Data on SOT109 for Colorectal Cancer

SOTIO Presents Promising Preclinical Data on SOT109 for Colorectal Cancer

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, has unveiled promising preclinical data on SOT109, a next-generation antibody-drug conjugate (ADC) targeting cadherin-17 (CDH17). These findings reinforce the strong therapeutic potential of SOT109 in treating colorectal cancer (CRC) and…

Read MoreSOTIO Presents Promising Preclinical Data on SOT109 for Colorectal Cancer

Protagonist and Takeda Report Positive Phase 3 VERIFY Study Results for Rusfertide in Polycythemia Vera

Protagonist and Takeda Announce Positive Phase 3 VERIFY Study Results for Rusfertide in Polycythemia Vera Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ: PTGX) and Takeda (TSE: 4502/NYSE: TAK) have announced positive topline results from the Phase 3 VERIFY study, evaluating rusfertide in…

Read MoreProtagonist and Takeda Report Positive Phase 3 VERIFY Study Results for Rusfertide in Polycythemia Vera
Seismic Therapeutic Presents Preclinical Data on S-8484 for Allergic Diseases

Seismic Therapeutic Presents Preclinical Data on S-8484 for Allergic Diseases

Seismic Therapeutic Presents Preclinical Data on S-8484 for Allergic Diseases Seismic Therapeutic, Inc., a pioneering machine learning immunology company, has announced the presentation of preclinical data for its novel immunoglobulin E (IgE) protease, S-8484. The data reveal S-8484’s ability to…

Read MoreSeismic Therapeutic Presents Preclinical Data on S-8484 for Allergic Diseases

Astria Begins Phase 3 ALPHA-ORBIT Trial of Navenibart for Hereditary Angioedema

Astria Begins Phase 3 ALPHA-ORBIT Trial of Navenibart for Hereditary Angioedema Astria Therapeutics, Inc. (Nasdaq: ATXS), a leading biopharmaceutical company dedicated to developing innovative therapies for allergic and immunological diseases, has officially launched the Phase 3 ALPHA-ORBIT clinical trial of…

Read MoreAstria Begins Phase 3 ALPHA-ORBIT Trial of Navenibart for Hereditary Angioedema